Treatments
Each dose, route and frequency of a medicine is its own treatment (a node), because 2.4 mg of semaglutide can work differently from 0.5 mg. Analyses are also run with the doses of each medicine pooled. GLP-1 receptor agonist containing treatments come first, then the comparators they were tested against.
Fixed ratio combination of basal insulin and GLP-1 receptor agonistGLP-1
GIP and GLP-1 receptor co-agonistGLP-1
- Tirzepatide 15 mg subcutaneous once weeklyTIRZ_SC_15MG_QW17 trials
- Tirzepatide 10 mg subcutaneous once weeklyTIRZ_SC_10MG_QW14 trials
- Tirzepatide 5 mg subcutaneous once weeklyTIRZ_SC_5MG_QW13 trials
- Tirzepatide maximum tolerated dose injection once weeklyTIRZ_SC_MTD_5-10-15_QW2 trials
- Tirzepatide subcutaneous once weekly, maximum tolerated dose: 10 or 15 mgTIRZ_SC_MTD_QW2 trials
- Tirzepatide 1 mg subcutaneous once weeklyTIRZ_SC_1MG_QW1 trial
- VK2735 2.5 mg injection once weeklyVK2735_SC_2p5MG_QW1 trial
- VK2735 5.0 mg injection once weeklyVK2735_SC_5p0MG_QW1 trial
- VK2735 10 mg injection once weeklyVK2735_SC_10MG_QW1 trial
- VK2735 15 mg injection once weeklyVK2735_SC_15MG_QW1 trial
- BGM0504 5 mg injection once weeklyBGM050_SC_5MG_QW1 trial
- BGM0504 10 mg injection once weeklyBGM050_SC_10MG_QW1 trial
- BGM0504 15 mg injection once weeklyBGM050_SC_15MG_QW1 trial
- Tirzepatide 12 mg injection once weeklyTIRZ_SC_12MG_QW1 trial
- Ct388 sc 12mg qwCT388_SC_12MG_QW1 trial
- CT-388 0.5 mg injectionCT388_SC_0p5MG_OTHER1 trial
- CT-388 2.0 mg injectionCT388_SC_2p0MG_OTHER1 trial
- CT-388 5.0 mg injectionCT388_SC_5p0MG_OTHER1 trial
- CT-388 6.0 mg injectionCT388_SC_6p0MG_OTHER1 trial
- CT-388 7.5 mg injectionCT388_SC_7p5MG_OTHER1 trial
- CT-388 7.5 mg injection once weeklyCT388_SC_7p5MG_QW1 trial
GIP receptor antagonist and GLP-1 receptor agonistGLP-1
GIP; GLP-1 and glucagon receptor tri-agonistGLP-1
- Retatrutide 4 mg subcutaneous once weeklyRETA_SC_4MG_QW2 trials
- Retatrutide 8 mg subcutaneous once weeklyRETA_SC_8MG_QW2 trials
- Retatrutide 12 mg subcutaneous once weeklyRETA_SC_12MG_QW2 trials
- Retatrutide 0.5 mg subcutaneous once weeklyRETA_SC_0p5MG_QW1 trial
- Retatrutide 1 mg subcutaneous once weeklyRETA_SC_1MG_QW1 trial
GLP-1 and GLP-2 receptor co-agonistGLP-1
GLP1_NEWGLP-1
- Safiglipron (HRS-7535) 30 mg tablet once dailySAFIGL_PO_30MG_QD3 trials
- Safiglipron (HRS-7535) 60 mg tablet once dailySAFIGL_PO_60MG_QD3 trials
- Safiglipron (HRS-7535) 90 mg tablet once dailySAFIGL_PO_90MG_QD3 trials
- Visepegenatide 150 µg injection once weeklyVISEPE_SC_150UG_QW2 trials
- Liraglutide plus metformin 1.2 to 1000 mg injection once dailyLIRAMETF_SC_1p2-1000MG_QD2 trials
- Dulaglutide with macupatide 1.5 to 20 mg injection once weeklyDULAMACU_SC_1p5-20MG_QW1 trial
- Liraglutide and empagliflozin 1.8 to 25 mg injection once dailyEMPALIRA_SC_1p8-25MG_QD1 trial
- Semaglutide and bimagrumab 1.0 to 10 mg injection once weeklyBIMASEMA_SC_1p0-10MG_QW1 trial
- Semaglutide and bimagrumab 2.4 to 10 mg injection once weeklyBIMASEMA_SC_2p4-10MG_QW1 trial
- Semaglutide and bimagrumab 1.0 to 30 mg injection once weeklyBIMASEMA_SC_1p0-30MG_QW1 trial
- Semaglutide and bimagrumab 2.4 to 30 mg injection once weeklyBIMASEMA_SC_2p4-30MG_QW1 trial
- Exenatide extended release and dapagliflozin 2 to 10 mg injection once weeklyDAPAEXEN_SC_2-10MG_QW1 trial
- Safiglipron (HRS-7535) 15 mg tablet once dailySAFIGL_PO_15MG_QD1 trial
- Exenatide and rosiglitazone 10 to 4 µg injection twice dailyEXENROSI_SC_10-4UG_BID1 trial
- Exenatide extended release and dapagliflozin 2 to 10 mg injection once weeklyEXENER_SC_2-10MG_QW1 trial
- Liraglutide plus canagliflozin 1.8 to 300 mg injection once dailyCANALIRA_SC_1p8-300MG_QD1 trial
- Exenatide extended release plus pioglitazone 2 to 30 mg injection once weeklyEXENER_SC_2-30MG_QW1 trial
- Efsubaglutide alfa 3 mg injection once weeklyEFSUBA_SC_3MG_QW1 trial
- Dulaglutide and dapagliflozin 1.5 to 10 mg injection once weeklyDAPADULA_SC_1p5-10MG_QW1 trial
- TERN-601 250 mg tablet once dailyTERN60_PO_250MG_QD1 trial
- Tern60 po 500mg qdTERN60_PO_500MG_QD1 trial
- TERN-601 750 mg tablet once dailyTERN60_PO_750MG_QD1 trial
- PEG-loxenatide 75 µg injection once weeklyPEGYLA_SC_75UG_QW1 trial
- PEG-loxenatide 150 µg injection once weeklyPEGYLA_SC_150UG_QW1 trial
- PEG-loxenatide 200 µg injection once weeklyPEGYLA_SC_200UG_QW1 trial
- Liraglutide after insulin degludec 0.9 mg injection once dailyLIRAGL_SC_0p9MG_QD1 trial
- ECC5004 5 mg tablet once dailyECC500_PO_5MG_QD1 trial
- ECC5004 10 mg tablet once dailyECC500_PO_10MG_QD1 trial
- ECC5004 30 mg tablet once dailyECC500_PO_30MG_QD1 trial
- ECC5004 50 mg tablet once dailyECC500_PO_50MG_QD1 trial
- Liraglutide and metformin 1.2 to 0.85 mg injection once dailyLIRAMETF_SC_1p2-0p85MG_QD1 trial
- Liraglutide and metformin 1.2 to 1500 mg injection once dailyLIRAMETF_SC_1p2-1500MG_QD1 trial
Glucagon and GLP-1 receptor co-agonistGLP-1
- Mazdutide 3 mg subcutaneous once weeklyMAZD_SC_3MG_QW3 trials
- Mazdutide 4.5 mg subcutaneous once weeklyMAZD_SC_4p5MG_QW3 trials
- Mazdutide 6 mg subcutaneous once weeklyMAZD_SC_6MG_QW3 trials
- Cotadutide 300 ug subcutaneous once dailyCOTA_SC_300UG_QD3 trials
- Cotadutide 100 ug subcutaneous once dailyCOTA_SC_100UG_QD1 trial
- Cotadutide 200 ug subcutaneous once dailyCOTA_SC_200UG_QD1 trial
- Mazdutide 16 mg injection once weeklyMAZD_SC_16MG_QW1 trial
- Survodutide 6.0 mg subcutaneous once weeklySURV_SC_6p0MG_QW1 trial
- Survodutide 0.6 mg subcutaneous once weeklySURV_SC_0p6MG_QW1 trial
- Survodutide 2.4 mg subcutaneous once weeklySURV_SC_2p4MG_QW1 trial
- Survodutide 3.6 mg subcutaneous once weeklySURV_SC_3p6MG_QW1 trial
- Survodutide 4.8 mg subcutaneous once weeklySURV_SC_4p8MG_QW1 trial
Long acting GLP-1 receptor agonist (injectable)GLP-1
- Liraglutide 1.8 mg subcutaneous once dailyLIRA_SC_1p8MG_QD54 trials
- Semaglutide 1.0 mg subcutaneous once weeklySEMA_SC_1p0MG_QW35 trials
- Dulaglutide 1.5 mg subcutaneous once weeklyDULA_SC_1p5MG_QW28 trials
- Liraglutide 3.0 mg subcutaneous once dailyLIRA_SC_3p0MG_QD24 trials
- Exenatide extended release 2 mg subcutaneous once weeklyEXENER_SC_2MG_QW23 trials
- Liraglutide 1.2 mg subcutaneous once dailyLIRA_SC_1p2MG_QD18 trials
- Dulaglutide 0.75 mg subcutaneous once weeklyDULA_SC_0p75MG_QW17 trials
- Semaglutide 2.4 mg subcutaneous once weeklySEMA_SC_2p4MG_QW15 trials
- Semaglutide 0.5 mg subcutaneous once weeklySEMA_SC_0p5MG_QW13 trials
- Liraglutide 0.9 mg injection once dailyLIRA_SC_0p9MG_QD12 trials
- Taspoglutide 20 mg subcutaneous once weeklyTASP_SC_20MG_QW5 trials
- Liraglutide 0.6 mg subcutaneous once dailyLIRA_SC_0p6MG_QD5 trials
- Taspoglutide 10 mg subcutaneous once weeklyTASP_SC_10MG_QW4 trials
- Liraglutide flexible dose injection once dailyLIRA_SC_FLEX_0p6-1p2-1p8_QD4 trials
- Semaglutide 2.0 mg subcutaneous once weeklySEMA_SC_2p0MG_QW4 trials
- Liraglutide subcutaneous once daily, flexible dose: 1.2 or 1.8 mg by tolerabilityLIRA_SC_FLEX_QD4 trials
- Albiglutide 30 mg subcutaneous once weeklyALBI_SC_30MG_QW3 trials
- Semaglutide 0.4 mg injection once dailySEMA_SC_0p4MG_QD3 trials
- Efpeglenatide 6 mg subcutaneous once weeklyEFPE_SC_6MG_QW3 trials
- Albiglutide 50 mg subcutaneous once weeklyALBI_SC_50MG_QW3 trials
- Dulaglutide 1.0 mg injection once weeklyDULA_SC_1p0MG_QW2 trials
- Dulaglutide 3.0 mg subcutaneous once weeklyDULA_SC_3p0MG_QW2 trials
- Dulaglutide 4.5 mg subcutaneous once weeklyDULA_SC_4p5MG_QW2 trials
- Albiglutide flexible dose injection once weeklyALBI_SC_FLEX_30-50_QW2 trials
- Dulaglutide 0.5 mg injection once weeklyDULA_SC_0p5MG_QW2 trials
- Dulaglutide flexible dose injection once weeklyDULA_SC_FLEX_0p75-1p5_QW2 trials
- Efpeglenatide 4 mg subcutaneous once weeklyEFPE_SC_4MG_QW2 trials
- Semaglutide 0.1 mg injection once dailySEMA_SC_0p1MG_QD2 trials
- Semaglutide 0.2 mg injection once dailySEMA_SC_0p2MG_QD2 trials
- Liraglutide 2.4 mg injection once dailyLIRA_SC_2p4MG_QD2 trials
- Polyethylene glycol loxenatide 0.2 mg subcutaneous once weeklyPEGLOX_SC_0p2MG_QW2 trials
- Albiglutide 100 mg injection every 4 weeksALBI_SC_100MG_Q4W1 trial
- Albiglutide 4 mg injection once weeklyALBI_SC_4MG_QW1 trial
- Albiglutide 15 mg injection once weeklyALBI_SC_15MG_QW1 trial
- Albiglutide 15 mg injection every 2 weeksALBI_SC_15MG_Q2W1 trial
- Albiglutide 30 mg injection every 2 weeksALBI_SC_30MG_Q2W1 trial
- Albiglutide 50 mg injection every 2 weeksALBI_SC_50MG_Q2W1 trial
- Albiglutide 50 mg injection every 4 weeksALBI_SC_50MG_Q4W1 trial
- Liraglutide flexible dose injection once dailyLIRA_SC_FLEX_1p2-1p8_QD1 trial
- Semaglutide maximum tolerated dose injection once weeklySEMA_SC_MTD_1p7-2p4_QW1 trial
- Liraglutide maximum tolerated dose injection once dailyLIRA_SC_MTD_0p6-1p2-1p8-2p4-3p0_QD1 trial
- Dulaglutide 0.25 mg injection once weeklyDULA_SC_0p25MG_QW1 trial
- Dulaglutide 2.0 mg injection once weeklyDULA_SC_2p0MG_QW1 trial
- Dulaglutide 0.1 mg injection once weeklyDULA_SC_0p1MG_QW1 trial
- Efpeglenatide 2 mg subcutaneous once weeklyEFPE_SC_2MG_QW1 trial
- Efpeglenatide 16 mg injection monthlyEFPE_SC_16MG_QM1 trial
- Exenatide extended release 0.8 mg injection once weeklyEXENER_SC_0p8MG_QW1 trial
- Semaglutide flexible dose injection once weeklySEMA_SC_FLEX_0p25-0p5-1p0_QW1 trial
- Efpeglenatide 8 mg injection every 4 weeksEFPE_SC_8MG_Q4W1 trial
- Efpeglenatide 12 mg injection every 4 weeksEFPE_SC_12MG_Q4W1 trial
- Efpeglenatide 16 mg injection every 4 weeksEFPE_SC_16MG_Q4W1 trial
- Efpeglenatide 6 mg injection every 2 weeksEFPE_SC_6MG_Q2W1 trial
- Efpeglenatide 8 mg injection every 2 weeksEFPE_SC_8MG_Q2W1 trial
- Liraglutide maximum tolerated dose injection once dailyLIRA_SC_MTD_0p3-0p6-0p9-1p2-1p8-2p4-3p0_QD1 trial
- Semaglutide 8 mg injection once weeklySEMA_SC_8MG_QW1 trial
- Semaglutide 16 mg injection once weeklySEMA_SC_16MG_QW1 trial
- Taspoglutide 30 mg injection once weeklyTASP_SC_30MG_QW1 trial
- Taspoglutide 40 mg injection once weeklyTASP_SC_40MG_QW1 trial
- Exenatide (ITCA 650 implant) 20 ug implant continuousEXENIMP_IMPLANT_20UG_CONT1 trial
- Exenatide (ITCA 650 implant) 40 µg implant continuousEXENIMP_IMPLANT_40UG_CONT1 trial
- Taspoglutide 5 mg injection once weeklyTASP_SC_5MG_QW1 trial
- Taspoglutide 10 mg injection every 2 weeksTASP_SC_10MG_Q2W1 trial
- Taspoglutide 20 mg injection every 2 weeksTASP_SC_20MG_Q2W1 trial
- Liraglutide maximum tolerated dose injection once dailyLIRA_SC_MTD_0p6-1p2-1p8_QD1 trial
- Semaglutide 1.7 mg injection once weeklySEMA_SC_1p7MG_QW1 trial
- Ebenatide 2 mg injection once weeklyEBENAT_SC_2MG_QW1 trial
- Semaglutide flexible dose injection once weeklySEMA_SC_FLEX_0p5-1p0_QW1 trial
- Semaglutide 0.05 mg injection once dailySEMA_SC_0p05MG_QD1 trial
- Semaglutide 0.3 mg injection once dailySEMA_SC_0p3MG_QD1 trial
- Bofanglutide (GZR18) 4 mg injection once weeklyBOFANG_SC_4MG_QW1 trial
- Bofanglutide 12 mg injection every 2 weeksBOFANG_SC_12MG_Q2W1 trial
- Bofanglutide 18 mg injection every 2 weeksBOFANG_SC_18MG_Q2W1 trial
- Bofanglutide 24 mg injection every 2 weeksBOFANG_SC_24MG_Q2W1 trial
- Bofanglutide 48 mg injection every 2 weeksBOFANG_SC_48MG_Q2W1 trial
- Bofanglutide 24 mg injection once weeklyBOFANG_SC_24MG_QW1 trial
- Polyethylene glycol loxenatide 300 µg injection once weeklyPEGLOX_SC_300UG_QW1 trial
- Polyethylene glycol loxenatide 400 µg injection once weeklyPEGLOX_SC_400UG_QW1 trial
- Ecnoglutide 0.4 mg injection once weeklyECNO_SC_0p4MG_QW1 trial
- Ecnoglutide 0.8 mg injection once weeklyECNO_SC_0p8MG_QW1 trial
- Ecnoglutide 1.2 mg injection once weeklyECNO_SC_1p2MG_QW1 trial
- Polyethylene glycol loxenatide 0.3 mg injection once weeklyPEGLOX_SC_0p3MG_QW1 trial
- Liraglutide 1.2 mg injectionLIRA_SC_1p2MG_OTHER1 trial
- TG103 15 mg injection once weeklyTG103_SC_15MG_QW1 trial
- TG103 22.5 mg injection once weeklyTG103_SC_22p5MG_QW1 trial
- TG103 30 mg injection once weeklyTG103_SC_30MG_QW1 trial
Oral peptide GLP-1 receptor agonistGLP-1
- Semaglutide 14 mg oral once daily (original tablet)SEMA_PO_14MG_QD12 trials
- Semaglutide 7 mg oral once daily (original tablet)SEMA_PO_7MG_QD9 trials
- Semaglutide 3 mg oral once daily (original tablet)SEMA_PO_3MG_QD7 trials
- Semaglutide oral once daily (original tablet), flexible dose: 3, 7 or 14 mg adjusted by HbA1c and tolerabilitySEMA_PO_FLEX_QD1 trial
- Semaglutide 50 mg oral once daily (higher dose oral program)SEMA_PO_50MG_QD1 trial
Oral small molecule GLP-1 receptor agonistGLP-1
- Orforglipron 12 mg oral once dailyORFO_PO_12MG_QD8 trials
- Orforglipron 36 mg oral once dailyORFO_PO_36MG_QD7 trials
- Danuglipron 80 mg oral twice dailyDANU_PO_80MG_BID3 trials
- Danuglipron 40 mg oral twice dailyDANU_PO_40MG_BID3 trials
- Danuglipron 120 mg oral twice dailyDANU_PO_120MG_BID3 trials
- Orforglipron 3 mg oral once dailyORFO_PO_3MG_QD3 trials
- Orforglipron 24 mg oral once dailyORFO_PO_24MG_QD3 trials
- Orforglipron 45 mg oral once dailyORFO_PO_45MG_QD3 trials
- Orforglipron 6 mg oral once dailyORFO_PO_6MG_QD2 trials
- HRS-7535 30 mg tablet once dailyHRS7535_PO_30MG_QD2 trials
- Danuglipron 200 mg oral twice dailyDANU_PO_200MG_BID1 trial
- Danuglipron 140 mg tablet twice dailyDANU_PO_140MG_BID1 trial
- Danuglipron 160 mg oral twice dailyDANU_PO_160MG_BID1 trial
- Lotiglipron 140 mg tablet once dailyLOTI_PO_140MG_QD1 trial
- Loti po 200mg qdLOTI_PO_200MG_QD1 trial
- Lotiglipron 260 mg tablet once dailyLOTI_PO_260MG_QD1 trial
- Lotiglipron 20 mg tablet once dailyLOTI_PO_20MG_QD1 trial
- Lotiglipron 40 mg tablet once dailyLOTI_PO_40MG_QD1 trial
- Lotiglipron 80 mg tablet once dailyLOTI_PO_80MG_QD1 trial
- Lotiglipron 160 mg tablet once dailyLOTI_PO_160MG_QD1 trial
- Aleniglipron 45 mg tablet once dailyALENIG_PO_45MG_QD1 trial
- Aleniglipron 90 mg tablet once dailyALENIG_PO_90MG_QD1 trial
- Aleniglipron 120 mg tablet once dailyALENIG_PO_120MG_QD1 trial
- Danuglipron 2.5 mg tablet twice dailyDANU_PO_2p5MG_BID1 trial
- Danuglipron 10 mg tablet twice dailyDANU_PO_10MG_BID1 trial
- HRS-7535 90 mg tablet once dailyHRS7535_PO_90MG_QD1 trial
- Orforglipron maximum tolerated dose tablet once dailyORFO_PO_MTD_24-36_QD1 trial
- HRS-7535 60 mg tablet once dailyHRS7535_PO_60MG_QD1 trial
- HRS-7535 120 mg tablet once dailyHRS7535_PO_120MG_QD1 trial
- HRS-7535 180 mg tablet once dailyHRS7535_PO_180MG_QD1 trial
- VCT220 80 mg tablet once dailyVCT220_PO_80MG_QD1 trial
- VCT220 120 mg tablet once dailyVCT220_PO_120MG_QD1 trial
- Vct220 po 160mg qdVCT220_PO_160MG_QD1 trial
Short acting GLP-1 receptor agonist (injectable)GLP-1
- Exenatide 10 ug subcutaneous twice dailyEXEN_SC_10UG_BID40 trials
- Lixisenatide 20 ug subcutaneous once dailyLIXI_SC_20UG_QD22 trials
- Exenatide 5 ug subcutaneous twice dailyEXEN_SC_5UG_BID4 trials
- Lixisenatide 30 µg injection once dailyLIXI_SC_30UG_QD2 trials
- Lixisenatide 30 µg injection twice dailyLIXI_SC_30UG_BID2 trials
- Beinaglutide 0.2 mg subcutaneous three times dailyBEIN_SC_0p2MG_TID1 trial
- Lixisenatide 5 µg injection once dailyLIXI_SC_5UG_QD1 trial
- Lixisenatide 10 µg injection once dailyLIXI_SC_10UG_QD1 trial
- Lixisenatide 5 µg injection twice dailyLIXI_SC_5UG_BID1 trial
- Lixisenatide 10 µg injection twice dailyLIXI_SC_10UG_BID1 trial
- Lixisenatide 20 µg injection twice dailyLIXI_SC_20UG_BID1 trial
- Exenatide 2.5 µg injection twice dailyEXEN_SC_2p5UG_BID1 trial
- Beinaglutide flexible dose injection three times dailyBEIN_SC_FLEX_0p1-0p2_TID1 trial
Basal insulin
DPP-4 inhibitor
Lifestyle intervention
Metformin
Other active comparator
- Basal bolus insulinOTHER_ACTIVE_basal_bolus_insulin7 trials
- Dpp4 inhibitorOTHER_ACTIVE_dpp4_inhibitor2 trials
- MacupatideOTHER_ACTIVE_macupatide1 trial
- TestosteroneOTHER_ACTIVE_testosterone1 trial
- Botulinum toxinOTHER_ACTIVE_botulinum_toxin1 trial
- Sequential metformin sulfonylurea insulinOTHER_ACTIVE_sequential_metformin_sulfonylurea_insulin1 trial
- Investigator choice oral drugOTHER_ACTIVE_investigator_choice_oral_drug1 trial
- Basal insulinOTHER_ACTIVE_basal_insulin1 trial
- BimagrumabOTHER_ACTIVE_bimagrumab1 trial
- SulfonylureaOTHER_ACTIVE_sulfonylurea1 trial
- Additional oadOTHER_ACTIVE_additional_OAD1 trial
- CagrilintideOTHER_ACTIVE_cagrilintide1 trial
- Cyproterone ethinylestradiolOTHER_ACTIVE_cyproterone_ethinylestradiol1 trial
- Glargine then metforminOTHER_ACTIVE_glargine_then_metformin1 trial
- Basal insulin sglt2iOTHER_ACTIVE_basal_insulin_sglt2i1 trial
- Insulin dose increaseOTHER_ACTIVE_insulin_dose_increase1 trial